›› 2012, Vol. 32 ›› Issue (11): 1426-.doi: 10.3969/j.issn.1674-8115.2012.11.007

• Monographic report (Pathogenic microbiology) • Previous Articles     Next Articles

Recombination, preparation and immunological evaluation of Mycobacterium tuberculosis specific antigen ESXO

FENG Li1, YE Juan2, WANG Feng-ping1, ZHAO Jun-wei3, WU Xing-fu1, ZHANG Shu-lin3   

  1. 1.Suzhou No.5 People's Hospital, Suzhou 215007, China;2.Department of Biochemistry, Henan University of Traditional Chinese Medicine, Zhengzhou 450008, China;3.Department of Microbiology and Parasitology, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
  • Online:2012-11-28 Published:2012-11-30
  • Supported by:

    National Natural Science Foundation of China, 81271794;Shanghai Science and Technology Committee Foundation, 12441903300


Objective To determine the expression of recombinant Mycobacterium tuberculosis (MTB) specific antigen ESXO in E.coli, and evaluate its immunogenicity. Methods Recombinant ESXO protein of MTB was obtained with conventional molecular cloning method. The serum antibody against ESXO was detected by enzyme linked immunosorbent assay (ELISA) in 84 patients with tuberculosis (TB) and 48 healthy controls, the serum immunogenicity was evaluated, and the results were compared with findings in detection of ESAT-6 and CFP-10 protein for serodiagnosis of TB. Results The recombinant specific antigen ESXO was expressed as soluble and inclusion body protein in E.coli BL21 plysS (DE3), with the relative molecular weight of 27 300, which was in line with expectations. The immunogenic evaluation of recombinant ESXO protein indicated that its specificity and sensitivity reached 94.0% (45/48) and 32.1% (27/84) respectively, which was equal to ESAT-6 and CFP-10 in specificity and higher than ESAT-6 in sensitivity. Conclusion The specific antigen ESXO is expected to be a novel candidate antigen for the diagnosis and vaccine design in TB.

Key words: Mycobacterium tuberculosis, clone, ESXO, gene expression, serodiagnosis